2024 latest purchase cost of Adagrasib

Adagrasib (Adagrasib) is a new type of targeted therapy developed by the biopharmaceutical company Mirati Therapeutics. It is the first K-RAS G12Cinhibitor to receive emergency use authorization from the U.S. Food and Drug Administration (FDA). Adagrasiib is primarily indicated for the treatment of locally advanced or metastatic KRAS G12C mutated non-small cell lung cancer in patients who have received at least one prior systemic therapy. In addition, it has also been researched used to treat other types of tumors, such as pancreatic cancer, colorectal cancer, etc.

The mechanism of action of adagrasib is to specifically inhibit KRAS G12C mutant, locking the mutated KRAS protein in its inactive state, thereby preventing downstream signaling, inhibiting the proliferation and metastasis of tumor cells, and promoting tumor cell apoptosis. This drug has better efficacy and milder side effects, and can improve patients' survival rate and quality of life compared with traditional chemotherapy and radiotherapy. Before using adagrasib, genetic testing is required to ensure the patient is suitable for the drug.

Sinceadagrasibthe original drug has not yet been launched in China, patients can only purchase adagrasib through overseas channels, and the U.S. original version of 200mg*180 tablets is priced at hundreds of thousands of yuan per box (the price may fluctuate due to exchange rates), which is very expensive. Currently, there are no generic drugs of adagrasib produced overseas. Although adagrasib has a higher price, it is still an important new anti-cancer drug, providing a better treatment option for K-RAS G12C mutant-positive tumor patients. For more drug information and specific prices, please consult Yaode’s medical consultant.